Cell and Gene Therapy Catapult facility in Stevenage, UK

Ger­many's Rentschler looks to build UK foot­print with five-year in­vest­ment in cell and gene ther­a­pies

Look­ing to add an­oth­er ca­pa­bil­i­ty to its ar­se­nal, Ger­man CD­MO Rentschler Bio­phar­ma will bump up its in­vest­ment in cell and gene ther­a­pies over the next five years through a new site at the Cell and Gene Ther­a­py Cat­a­pult in the UK.

Lo­cat­ed in Steve­nage, Eng­land, the site will al­low Rentschler to es­tab­lish the man­u­fac­tur­ing of vi­ral vec­tors for clin­i­cal sup­ply. The com­pa­ny ex­pects to be ready for cGMP man­u­fac­tur­ing by the first half of 2022 and will al­so es­tab­lish man­u­fac­tur­ing ca­pa­bil­i­ty in ad­vanced ther­a­py med­i­c­i­nal prod­ucts, in­clud­ing ade­no-as­so­ci­at­ed virus vec­tors for clin­i­cal tri­al sup­ply.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.